Stille (STIL.ST) Stock Analysis & AI Equity Report
Stille (STIL.ST) overview
Stille (STIL.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Stille reported revenue of SEK 568m and operating profit of SEK 72.7m; the year-end share price was 196.00 SEK and market capitalisation was SEK 1,761m. Stille is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Stille's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Stille
Stille AB develops, manufactures and markets premium surgical instruments and advanced surgical tables for hospitals and surgeons. Its product range includes reusable hand instruments for open surgery and C-arm tables used in minimally invasive procedures, with sales supported through a network of distributors and direct customer relationships in selected medical niches.
Generate the Stille report
Stille is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Stille and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.